Table 3B.
Antibody and IGRA titres two (T2) and six months (T3) after vaccination in the seroconverted pure vaccination cohort dependent on vaccine type.
| Variable | Group | Time point | Category | BNT162b2 mRNA | mRNA-1273 | p-value (Mann-Whitney test) |
|---|---|---|---|---|---|---|
| Humoral responses | ||||||
| IgA-Ab Spike S1 | MP | T2 | Median (interquartile range) | 4·3 (2·3–6·8) | 9 (8·4–9) | < 0·001 |
| IgA-Ab Spike S1 | MP | T3 | Median (interquartile range) | 1·7 (1·0–3·3) | 4·2 (2·3–6) | < 0·001 |
| IgA-Ab Spike S1 | DP | T2 | Median (interquartile range) | 3·7 (1·5–7·1) | 8·8 (5·1–9) | < 0·001 |
| IgA-Ab Spike S1 | DP | T3 | Median (interquartile range) | 0·9 (0·4–1·8) | 2·2 (1·0–4·8) | < 0·001 |
| IgA-Ab Spike S1 | KTR | T2 | Median (interquartile range) | 2·9 (1·5–5·7) | 5·8 (2·6–9) | 0·007 |
| IgA-Ab Spike S1 | KTR | T3 | Median (interquartile range) | 1·6 (0·6–2·8) | 2·0 (0·9–4·7) | 0·051 |
| IgG-Ab Spike S1 | MP | T2 | Median (interquartile range) | 384 (384–384) | 384 (384–384) | 0·12 |
| IgG-Ab Spike S1 | MP | T3 | Median (interquartile range) | 241·5 (101·1–325·2) | 384 (266·7–384) | < 0·001 |
| IgG-Ab Spike S1 | DP | T2 | Median (interquartile range) | 384 (194·3–384) | 384 (384–384) | < 0·001 |
| IgG-Ab Spike S1 | DP | T3 | Median (interquartile range) | 68·6 (25·1–133·5) | 224·3 (108·7–384) | < 0·001 |
| IgG-Ab Spike S1 | KTR | T2 | Median (interquartile range) | 201·9 (90·1–384) | 384 (126·9–384) | 0·086 |
| IgG-Ab Spike S1 | KTR | T3 | Median (interquartile range) | 99·8 (31·9–184·5) | 125·0 (65·6–344·8) | 0·051 |
| RBD | MP | T2 | Median (interquartile range) | 98·7 (974–99·4) | 99·4 (99·1–99·6) | < 0·001 |
| RBD | MP | T3 | Median (interquartile range) | 82·1 (69·3–91·6) | 91·6 (83·1–97·2) | 0·001 |
| RBD | DP | T2 | Median (interquartile range) | 80·6 (57·8–95·3) | 98·4 (93·5–99·4) | < 0·001 |
| RBD | DP | T3 | Median (interquartile range) | 27·8 (9·9–47·5) | 63·8 (31·6–87·5) | < 0·001 |
| RBD | KTR | T2 | Median (interquartile range) | 56·9 (32·6–77·8) | 76·5 (40·5–97·5) | 0·018 |
| RBD | KTR | T3 | Median (interquartile range) | 35·9 (16·9–48·4) | 45·5 (21·7–81·5) | 0·072 |
| IGRA– T-cellular response | ||||||
| IGRA | MP | T2 | Median (interquartile range) | 1593·3 (740·2–2474·5) | 2413·8 (1454·7–2490·3) | 0·198 |
| IGRA | MP | T3 | Median (interquartile range) | 453·1 (200·9–1183·5) | 700·0 (481·2–2461·5) | 0·144 |
| IGRA | DP | T2 | Median (interquartile range) | 732·6 (154·5–2479·1) | 1021·17 (366·4–2477·4) | 0·364 |
| IGRA | DP | T3 | Median (interquartile range) | 256·9 (34·7–1387·1) | 428·9 (101·6–1161·4) | 0·485 |
| IGRA | KTR | T2 | Median (interquartile range) | 138·4 (14·5–326·4) | 43·8 (11·1–282·6) | 0·554 |
| IGRA | KTR | T3 | Median (interquartile range) | 75·6 (12·8–173·8) | 25·9 (16·0–244·4) | 0·627 |
MP = Medical Personnel; DP = Dialysis Patients; KTR = Kidney Transplant Recipient; Interferon-γ release assay = IGRA;
This table compares the average titre levels (median/interquartile range) of 2x BNT162b2mRNA or 2×1273-mRNA (different columns) vaccinated study participants on T2 (two months) and T3 (six months) (different columns) for the different anti-Spike S1 IgA, IgG, RBD-IgG antibodies as well as for cellular immunity via IGRA measurements. For this evaluation, all participants with asymptomatic* or documented symptomatic** COVID-19 disease before and during vaccination up to T3 (six months) were excluded.
*Asymptomatic COVID-19 disease definition - neither knowledge nor symptoms of COVID-19 disease, but IgG-antibody reaction to nucleocapsid (T0, T2 or T3) or to the Spike protein subunit S1 (only T0) of the SARS-CoV-2 virus is positive.
**Symptomatic COVID-19 disease definition - SARS-CoV-2 PCR positive patients with clinical symptoms.